Improving Outcomes for Stem Cell Transplant Recipients: Pioneering Biomarkers in Human Cytomegalovirus Infection

Human cytomegalovirus (HCMV) remains in healthy humans in a dormant state for life without causing major disease, but can periodically awaken (reactivate) and form new virus. In cancer patients needing a stem cell transplant, reactivation can cause very serious disease. Despite this, little is known about how best to predict whether HCMV will cause serious infection. This project will define early biomarkers of HCMV severity to guide new therapies to limit the impact of HCMV on these patients.